Testing, one, two, three.......
Testing, one, two, three.......
Is this thing live??
These were exchanges of $70 million worth of second-tiers that are doing their best, while loaded with potential block-buster projects, to make it back to third-tier....... companies with serious programs addressing unmet needs.
I have no concept of what is going on. I *hope* that it was a move by someone interested in sector consolidation. I'm not trying to imply that the two companies might be merged, but.......
For $230 million in research premium, you buy Antrin, at least two NAALADase inhibitors, Gliadel (non-RPR), NIL-A (non-Amgen), the paclitaxel project, Gd-Tex, about $170 million in cash cushion, and other neat stuff.
Nobody seems to care. The entire world has gone nuts. |
